Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice

Normark, 2001, Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin, CID, 32, 552, 10.1086/318697

Zhanel KD, 2015, Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae, J. Antimicrob. Chemother., 3170

Bryce, 2005, WHO estimates of the causes of death in children, Lancet, 365, 1147, 10.1016/S0140-6736(05)71877-8

Park, 2007, Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae, J. Clin. Microbiol., 45, 1225, 10.1128/JCM.02199-06

Pletz, 2008, Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species, Int. J. Antimicrob. Agents, 32, 199, 10.1016/j.ijantimicag.2008.01.021

Marriott, 2006, Streptococcus pneumoniae: the role of apoptosis in host defense and pathogenesis, Int. J. Biochem. Cell Biol., 38, 1848, 10.1016/j.biocel.2006.06.001

Whitney, 2003, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine, N. Engl. J. Med., 348, 1737, 10.1056/NEJMoa022823

SHINEFIELD-M, 2000, Efficacy of pneumococcal conjugate vaccines in largescale field trials, Pediatr. Infect. Dis. J., 19, 394, 10.1097/00006454-200004000-00036

ED, 1991, The protective efficacy of polyvalent pneumococcal polysaccharide vaccine, N. Engl. J. Med., 325, 1453, 10.1056/NEJM199111213252101

Hsu, 2009, Effect of pneumococcal conjugate vaccine on pneumococcal meningitis, N. Engl. J. Med., 360, 244, 10.1056/NEJMoa0800836

Hicks, 2007, Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004, J. Infect. Dis., 196, 1346, 10.1086/521626

RJ, 2007, Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage, J. Am. Med. Assoc., 297, 1784, 10.1001/jama.297.16.1784

Saxenian, 2011, An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines, Health Aff., 30, 1122, 10.1377/hlthaff.2011.0332

Barocchi, 2007, Vaccines in the era of genomics: the pneumococcal challenge, Vaccine, 25, 2963, 10.1016/j.vaccine.2007.01.065

B, 2000, C3 as substrate for adhesion of Streptococcus pneumoniae, JID (J. Infect. Dis.), 182, 497, 10.1086/315722

Lin, 2015, Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae, Microb. Pathog., 83–84, 35, 10.1016/j.micpath.2015.04.006

Dominguez-Huttinger, 2017, Mathematical modeling of Streptococcus pneumoniae colonization, invasive infection and treatment, Front. Physiol., 8, 115, 10.3389/fphys.2017.00115

Cheng, 2000, Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae, Biochemistry, 39, 5450, 10.1021/bi992157d

Zysk, 2001, Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae, Infect. Immun., 69, 845, 10.1128/IAI.69.2.845-852.2001

Gosink, 2000, Role of novel choline binding proteins in virulence of Streptococcus pneumoniae, Infect. Immun., 68, 5690, 10.1128/IAI.68.10.5690-5695.2000

J, 1990, 58, 3293

Ren, 2012, The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro, Clin. Vaccine Immunol. : CVI, 19, 1574, 10.1128/CVI.00393-12

Ren, 2003, Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface, Infect. Immun., 72, 114, 10.1128/IAI.72.1.114-122.2004

A-HT, 1999, Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae, Infect. Immun., 67, 4720, 10.1128/IAI.67.9.4720-4724.1999

Mukerji, 2012, Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine, J. Immunol., 189, 5327, 10.4049/jimmunol.1201967

DE, 1996, PspA, a protection-eliciting pneumococcal protein_ immunogenicity of isolated native PspA in mice, Vaccine, 14, 858, 10.1016/0264-410X(96)82948-3

DE, 2003, Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae, J. Infect. Dis., 188, 339, 10.1086/376571

Qian, 2012, Diversity of pneumococcal surface protein A (PspA) and relation to sequence typing in Streptococcus pneumoniae causing invasive disease in Chinese children. European journal of clinical microbiology & infectious diseases, Official Publication of the European Society of Clinical Microbiology, 31, 217, 10.1007/s10096-011-1296-9

Croney, 2012, PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clinical and vaccine immunology, CVI, 19, 891, 10.1128/CVI.05671-11

Brandileone, 2004, Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines, Vaccine, 22, 3890, 10.1016/j.vaccine.2004.04.009

Lu, 2015, Protective immune responses elicited by fusion protein containing PsaA and PspA fragments, Immunol. Invest., 44, 482, 10.3109/08820139.2015.1037956

van Roosmalen, 2006, Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria, Methods, 38, 144, 10.1016/j.ymeth.2005.09.015

Van Braeckel-Budimir, 2013, Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications, Front. Immunol., 4, 282, 10.3389/fimmu.2013.00282

Beall, 2000

Hollingshead, 2006, Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries, J. Med. Microbiol., 55, 215, 10.1099/jmm.0.46268-0

Oliveira, 2010, Combination of pneumococcal surface protein a (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice, PLoS One, 5, 10.1371/journal.pone.0010863

de Haan, 2012, Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration, Vaccine, 30, 4884, 10.1016/j.vaccine.2012.04.032

Keijzer, 2014, Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion, Vaccine, 32, 2904, 10.1016/j.vaccine.2014.02.019

Saluja, 2010, Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant, AAPS J., 12, 109, 10.1208/s12248-009-9168-2

Ramirez, 2010, Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine Carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection, Mucosal Immunology, 3, 159, 10.1038/mi.2009.131